Supyra®

S Kant Healthcare

Product category
  • Seasonal malaria chemoprevention (sulfadoxine-pyrimethamine + amodiaquine)

Therapeutic indication
  • Seasonal malaria chemoprevention (SMC) for children 3 to 59 months in eligible region

Dosing
  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months

Efficacy
  • 75% reduction in malaria episodes in pivotal trials

Key features
  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

  • Two-year shelf life

Challenges
  • Drug distribution to healthy subjects mainly via door-to-door campaigns
Status
  • The Global Fund ERP approved for one year until Feb 2020
  • Registered in 4 countries; ongoing in 5 other countries
  • Orders confirmed for >11 million treatments in 2019
Next milestone
  • WHO prequalification

  • Extension of the recommendation for children up to their 10th birthday
  •  Validation of the dose and development of a specific packaging for children from 5 years old up until their 10th birthday
  •  Exploration of expanded SMC coverage by adding a fifth monthly round of treatment in areas with longer seasonal transmission
MMV Project Director
  • Dr André-Marie Tchouatieu